ICI Boston will unite the pioneering drug developers who have successfully developed and implemented immune checkpoint modulator monotherapies and combinations.
Focused exclusively on identifying clinically effective combinations, validating patient selection biomarkers and assessing novel target pathways utilising the tumor microenvironment, this is the only forum to provide a balanced and comprehensive insight into the development of the next generation of IO therapeutic strategies.
Join the leaders in the field and leave with actionable insights that will enable you to make the right decisions with your IO pipeline to lay the foundations for future success.
"Great meeting, very informative, great to see what other companies are working on in the field of cancer immunotherapy."
"This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics."